↓ Skip to main content

The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies

Overview of attention for article published in BMC Cancer, April 2017
Altmetric Badge

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies
Published in
BMC Cancer, April 2017
DOI 10.1186/s12885-017-3211-y
Pubmed ID
Authors

Joanna Trubicka, Tomasz Żemojtel, Jochen Hecht, Katarzyna Falana, Dorota Piekutowska- Abramczuk, Rafał Płoski, Marta Perek-Polnik, Monika Drogosiewicz, Wiesława Grajkowska, Elżbieta Ciara, Elżbieta Moszczyńska, Bożenna Dembowska-Bagińska, Danuta Perek, Krystyna H. Chrzanowska, Małgorzata Krajewska-Walasek, Maria Łastowska

Abstract

The defects in DNA repair genes are potentially linked to development and response to therapy in medulloblastoma. Therefore the purpose of this study was to establish the spectrum and frequency of germline variants in selected DNA repair genes and their impact on response to chemotherapy in medulloblastoma patients. The following genes were investigated in 102 paediatric patients: MSH2 and RAD50 using targeted gene panel sequencing and NBN variants (p.I171V and p.K219fs*19) by Sanger sequencing. In three patients with presence of rare life-threatening adverse events (AE) and no detected variants in the analyzed genes, whole exome sequencing was performed. Based on combination of molecular and immunohistochemical evaluations tumors were divided into molecular subgroups. Presence of variants was tested for potential association with the occurrence of rare life-threatening AE and other clinical features. We have identified altogether six new potentially pathogenic variants in MSH2 (p.A733T and p.V606I), RAD50 (p.R1093*), FANCM (p.L694*), ERCC2 (p.R695C) and EXO1 (p.V738L), in addition to two known NBN variants. Five out of twelve patients with defects in either of MSH2, RAD50 and NBN genes suffered from rare life-threatening AE, more frequently than in control group (p = 0.0005). When all detected variants were taken into account, the majority of patients (8 out of 15) suffered from life-threatening toxicity during chemotherapy. Our results, based on the largest systematic study performed in a clinical setting, provide preliminary evidence for a link between defects in DNA repair genes and treatment related toxicity in children with medulloblastoma. The data suggest that patients with DNA repair gene variants could need special vigilance during and after courses of chemotherapy.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Unknown 43 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 23%
Student > Bachelor 9 20%
Student > Doctoral Student 5 11%
Student > Master 3 7%
Other 2 5%
Other 4 9%
Unknown 11 25%
Readers by discipline Count As %
Medicine and Dentistry 10 23%
Agricultural and Biological Sciences 9 20%
Biochemistry, Genetics and Molecular Biology 8 18%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Veterinary Science and Veterinary Medicine 1 2%
Other 2 5%
Unknown 12 27%